Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06037408 · ClinicalTrials.gov registry record · Phase 3
The Effect of N115 on Coughing in IPF Patients
A Phase 3 study, sponsored by Cellular Sciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 50
- Enrollment target
NCT06037408 is a Phase 3 study that has completed, run by Cellular Sciences. The registered enrollment target is 50 participants.
The verdict
NCT06037408, a Phase 3 study, has completed, sponsored by Cellular Sciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 50 participants
- Enrollment target
Study Summary
The purpose of this clinical trial is to administer a sodium pyruvate nasal spray that eliminates nasal oxidative stresses, caused by oxygen radicals, and demonstrate the efficacy of sodium pyruvate to reduce coughing and increase lung functions in patients with idiopathic pulmonary fibrosis. This will be a 21-day double-blinded randomized placebo-controlled trial designed to determine if patients with idiopathic pulmonary fibrosis treated with 20mM sodium pyruvate in 0.9% sodium chloride nasal spray solution will have reduced chronic coughing, as well as increased lung function (FEV1, FVC endpoints of 12% or more within the first week) and improved FEV1/FVC ratios.
Interventions
- DRUG 20mM sodium pyruvate nasal spray
- OTHER Saline Placebo control nasal spray
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2023-08-15 |
| Est. Completion | 2024-05-20 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06037408
The ClinicalTrials.gov registry entry for NCT06037408 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cellular Sciences, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 20mM sodium pyruvate nasal spray is the first listed.
NCT06037408 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06037408 about?
NCT06037408 is a clinical study titled "The Effect of N115 on Coughing in IPF Patients". The purpose of this clinical trial is to administer a sodium pyruvate nasal spray that eliminates nasal oxidative stresses, caused by oxygen radicals, and demonstrate the efficacy of sodium pyruvate to reduce coughing and increase lung functions in patients with idiopathic pulmonary fibrosis. This w...
What is the current status of trial NCT06037408?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 50 participants. The study started on 2023-08-15. Estimated completion is 2024-05-20.
What interventions are being tested in trial NCT06037408?
The interventions under investigation include: 20mM sodium pyruvate nasal spray (DRUG), Saline Placebo control nasal spray (OTHER).
Who is sponsoring clinical trial NCT06037408?
This trial is sponsored by Cellular Sciences, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.